Audit: QRS - Black Garlic Extract for Health & Longevity

Audit conducted on 17/08/2026 09:32 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to ER Therapeutic Protocol (lines 353, 355, 361), time cells to lines 408 and 184, benefits/risks to the ER tier headings, gates to Key Interactions & Contraindications (lines 306–329), monitoring rows to the ER biomarker table (lines 440–450), qualitative items to lines 454–458.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s hedges are carried through where they survive condensation — “Nothing has been demonstrated at 2–4 weeks” (time_1_sub), “evening dosing is defensible” (action_3_sub), “cholesterol results conflict” and “rest on laboratory work only” (at_a_glance).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	The pregnancy/breastfeeding entry stays in the Contraindications gate rather than being demoted to a caution; the saquinavir entry keeps absolute-contraindication placement; no hedge is upgraded to a positive claim.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gate content comes only from Key Interactions & Contraindications; benefits only from Expected Benefits; risks only from Potential Risks & Side Effects; monitoring and qualitative only from Monitoring Protocol & Defining Success. No Benefit-Modifying Factors or Risk-Modifying Factors content is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names, or brand names (ABG10+, Kyolic, Life Extension, Pharmactive) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	The only attributive phrases (“the whole-clove trial”, “the aged black garlic trial”, “the standardized extract trial”, “one trial”) are taken verbatim from the ER’s own Why column and Magnitude lines.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Detached, evidence-first register matching the ER; the ER’s own scepticism (“Potency varies enormously”, “rest on laboratory work only”) is preserved.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets and dose ranges carry the data; the At-A-Glance and Protocol panels frame what can be acted on without overselling.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as options and observations (“Standardized extract approach”, “Whole-food approach”) rather than as a prescription.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No diagnosis, prescription, or treatment directive; the footer disclaimer is intact and the monitoring cadence mirrors the ER’s own descriptive schedule.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “recommend”, “advise”, “should take”, or “we suggest” anywhere in the document.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns; the one near-personal construction, “those already near optimal should expect little” (at_a_glance), is third person.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to the named drugs, biomarkers, and enzyme families that the decision gates and monitoring table require.
2.8	Information is presented in a concise and very compact manner	🟢	684 visible words across the whole sheet; every gate and tier item is a compressed noun phrase.
2.9	It DOES NOT address the reader directly	🟢	No “you”, “your”, or direct imperative aimed at the reader.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The monitoring targets are optimal-range rather than clinical-cutoff values (hs-CRP <0.5 mg/L, ALT <20 U/L men, HbA1c 4.8–5.3%), which addresses the optimizing reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	An 11-marker laboratory panel, weekly home blood pressure, and a 12-week evaluation horizon all assume a reader willing to invest effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Apolipoprotein B is included although it is not in standard panels; targets sit below conventional thresholds throughout.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance closes with “those already near optimal should expect little”, carrying the ER’s key audience-specific caveat.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Gastrointestinal discomfort”, “erosive esophagitis”, “proton pump inhibitors”, “antiplatelet or anticoagulant therapy” are used rather than consumer equivalents.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings match the template byte-for-byte (lines 440, 477, 519, 539, 552, 571, 590, 594–596, 731 and the tier labels at 522–531 / 574–583).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names are present; the three repeatable groups are expanded to marker_1..11 (name/target/why) and qualitative_item_1..5, with no template span dropped.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three website-binding spans (website="evidence_review", website="audit", website="full_review") and the whole <style> block are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Standardized extract approach”, action_2_label “Whole-food approach”, and action_3_label “Time of day” are the ER’s bold Protocol labels verbatim; all eleven monitoring row labels match the ER Biomarker column verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No cell or row label is shortened or substituted; “Apolipoprotein B”, “Fasting glucose”, and “INR (warfarin users only)” are carried across unchanged.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	A codepoint scan of the file returns no emoji; the ER’s “⚠️ Conflicted” markers were correctly dropped, and tiers are conveyed by <strong> labels plus the card palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is materially condensed against the ER — 12 Protocol bullets to 3 cells, 15 benefit/risk headings to 8 tier lines, 8 interaction bullets to 7 one-line gates — and the sheet carries 684 visible words at 9–9.5pt card type.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: a single comment opening on line 2 immediately after <!doctype html> on line 1, closing on line 14 before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preceding descriptive text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It sits inside an HTML comment ahead of <html>, and none of its values are repeated in <body>.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: black_garlic_extract_2026-0825-0608_Opus_ER.md, matching the ER’s own filename frontmatter field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0817-0919, in the required YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: black_garlic_extract_2026-0825-0608_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; only the colon-bearing duration value is quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Black Garlic Extract for Health & Longevity - Quick Reference Sheet, matching the ER’s canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Black Garlic Extract for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/17/2026, the correct reformatting of 2026-0817-0919.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All five sentences map to the ER Conclusion (lines 478–484), in the same order the Conclusion presents them.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Aging/water-solubility → line 478; blood-pressure primacy and adjunctive framing → line 480; inflammation, antioxidant, and conflicting cholesterol → line 480; liver/cancer/brain laboratory-only → line 480; potency variability and near-optimal readers → lines 478 and 484.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms at all; “sulfur compounds”, “water-soluble”, “blood pressure”, “inflammation”, “cholesterol”, and “laboratory work” are all everyday terms. SAC, NF-κB, LDL-C, and hs-CRP are all correctly kept out.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No author name, year, registry ID, or participant count appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No mmHg values, confidence intervals, or risk ratios; the blood-pressure effect is described qualitatively as “a small, repeatable fall”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to the ER’s “Populations who should avoid Black Garlic Extract” list (lines 324–329) inside that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoid-populations are present, and the ER’s absolute saquinavir contraindication (line 308) is captured by the first item.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–547: six discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a bare noun phrase; the ER’s explanatory clauses (“for whom supplemental doses above culinary amounts are unstudied”, “ulcerated inflammation of the food pipe”) are stripped and no dash-trailed clause survives.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“platelet count below 100 × 10⁹/L”, “Within 14 days of scheduled surgery”, “(Los Angeles Grade C or D)”, and “(doses above culinary amounts)” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to the ER’s interaction bullets at lines 306–320.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s eight interaction bullets appear; the protease-inhibitor bullet is correctly excluded because it is carried in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 555–561: seven discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Caution —”, “Monitor —” prefixes and every trailing rationale (“each lowers blood pressure independently”, “to avoid blunted absorption”, “Stagger introductions by four weeks”) are stripped; no dash-trailed clause remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named drug list survives: warfarin/apixaban/rivaroxaban/clopidogrel/aspirin, chlorzoxazone/paracetamol/isoniazid, the six antihypertensives, metformin/chlorpropamide/glipizide/insulin, ibuprofen/naproxen/aspirin, and both supplement lists.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight such interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets at lines 353, 355, and 361.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose form and dose (standardized extract), the alternative whole-food dose, and timing are the three decisions a reader must make; the remaining ER bullets are competing preparations, pharmacokinetics, and modifier discussion.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER’s Therapeutic Protocol section contains twelve bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans are populated: “250–500 mg once daily” / “0.5% S-allyl-cysteine, giving 1.25–2.5 mg” (line 353), “6–12 g/day whole cloves” / split dosing and fructan load (lines 355, 365), “Morning with breakfast” / evening-dosing caveat (line 361).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure and inflammation markers at 6–12 weeks (ER line 408) and cardiac function at six months (ER line 184) are the only quantified time-to-effect horizons the ER gives.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High tier (blood pressure) → Medium tier (inflammatory markers) → Low tier (cardiac function in heart failure), matching the ER’s own benefit grading.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans are populated; the subs carry the ER’s “nothing has been demonstrated at 2–4 weeks”, the 12-week meaningful-trial statement, and the six-month ejection-fraction and quality-of-life result.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect information at lines 184, 388, and 408.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven listed benefits are the ER’s Expected Benefits subheadings (lines 152–216), with none added and none dropped.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare ER heading joined by semicolons; no Magnitude figure, confidence interval, funding caveat, or mechanism is carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four benefit spans.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain at least one item.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight listed risks are the ER’s Potential Risks & Side Effects subheadings (lines 240–288).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated at lines 573–584.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare ER heading; the relative risk of 1.79, the saquinavir halving, and the allicin/ajoene mechanism are all correctly omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four risk spans.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain at least one item.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Every row is drawn from the ER Monitoring Protocol & Defining Success biomarker table (lines 438–450).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eleven ER rows are present in ER order: home blood pressure, LDL-C, apolipoprotein B, triglycerides, HDL-C, hs-CRP, HbA1c, fasting glucose, uric acid, ALT, INR, with targets and Why text carried across faithfully.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 725 carries the full cadence — one-to-two-week baseline, weekly home blood pressure, 12-week panel, then 6–12 monthly, plus weekly INR for four weeks — matching ER lines 434 and 436.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items are the ER’s qualitative-marker bullets at lines 454–458.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five are present and unabridged: gastrointestinal symptoms in the first fortnight, lightheadedness on standing, breath and body odor, unusual bruising or gum bleeding, and exercise tolerance and perceived recovery.

Issues 17/08/2026 09:32

Pass rate 100.00%. No issues found.

Issues 17/08/2026 09:24

1. 4.5 — One-page budget overrun: marker_11_target (line 715) carries the full 116-character ER sentence into a Target column where every other value is ≤40 characters, and the sixth caution_items entry (line 560) runs 191 characters; neither was condensed for the one-page A4 budget.

Fixes 17/08/2026 09:24

1. 4.5 — INR target condensed: Shortened marker_11_target from “No black-garlic-specific target; hold the individual’s prescribed range and track deviation from their own pre-supplement baseline” to “Individual’s prescribed range; track deviation from pre-supplement baseline”, cutting the cell from 116 to 74 characters.
2. 4.5 — Supplement interaction item condensed: Rewrote the sixth caution_items entry as “Blood-pressure-lowering supplements (dietary nitrate, hibiscus, magnesium, potassium, coenzyme Q10) and blood-thinning ones (fish oil, ginkgo, ginger, vitamin E, nattokinase)”, restoring the ER’s split between the two mechanisms while trimming the item to fit the half-width gate.